Abstract:Background: Natural killer group 2D (NKG2D) is an activating receptor of natural killer (NK) cells and other lymphocytes that mediates lysis of malignant cells through recognition of stress-induced ligands such as MICA and MICB. Such ligands are broadly expressed by cancer cells of various origins and serve as targets for adoptive immunotherapy with effector cells endogenously expressing NKG2D or carrying an NKG2D-based chimeric antigen receptor (CAR). However, shedding or downregulation of NKG2D ligands (NKG2DL) can prevent NKG2D activation, resulting in escape of cancer cells from NKG2D-dependent immune surveillance. Methods: To enable tumor-specific targeting of NKG2D-expressing effector cells independent of membrane-anchored NKG2DLs, we generated a homodimeric recombinant antibody which harbors an N-terminal single-chain fragment variable (scFv) antibody domain for binding to NKG2D, linked via a human IgG4 Fc region to a second C-terminal scFv antibody domain for recognition of the tumor-associated antigen ErbB2 (HER2). The ability of this molecule, termed NKAB-ErbB2, to redirect NKG2D-expressing effector cells to ErbB2-positive tumor cells of different origins was investigated using peripheral blood mononuclear cells, ex vivo expanded NK cells, and NK and T cells engineered with an NKG2D-based chimeric receptor. Results: On its own, bispecific NKAB-ErbB2 increased lysis of ErbB2-positive breast carcinoma cells by peripheral blood-derived NK cells endogenously expressing NKG2D more effectively than an ErbB2-specific IgG1 mini-antibody able to induce antibody-dependent cell-mediated cytotoxicity via activation of CD16. Furthermore, NKAB-ErbB2 synergized with NK-92 cells or primary T cells engineered to express an NKG2D-CD3ζ chimeric antigen receptor (NKAR), leading to targeted cell killing and greatly enhanced antitumor activity, which remained unaffected by soluble MICA known as an inhibitor of NKG2D-mediated natural cytotoxicity. In an immunocompetent mouse glioblastoma model mimicking low or absent NKG2DL expression, the combination of NKAR-NK-92 cells and NKAB-ErbB2 effectively suppressed outgrowth of ErbB2-positive tumors, resulting in treatment-induced endogenous antitumor immunity and cures in the majority of animals. Conclusions: Our results demonstrate that combining an NKAB antibody with effector cells expressing an activating NKAR receptor represents a powerful and versatile approach to simultaneously enhance tumor antigen-specific as well as NKG2D-CAR and natural NKG2D-mediated cytotoxicity, which may be particularly useful to target tumors with heterogeneous target antigen expression.

Dual-functional super bispecific nano-antibodies derived from monoclonal antibodies potentiate the antitumor effect of innate immune cells

Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity

Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors

In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16.

Generating a Novel Bispecific Nanobody to Enhance Antitumor Activity

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Immunomodulating Nano-Adaptors Potentiate Antibody-Based Cancer Immunotherapy

Bi-specific antibody engagers for cancer immunotherapy

In Vivo Self‐Assembled Bispecific Nano‐Blocker for Enhancing Tumor Immunotherapy

Bispecific Antibody Simultaneously Targeting PD1 and HER2 Inhibits Tumor Growth Via Direct Tumor Cell Killing in Combination with PD1/PDL1 Blockade and HER2 Inhibition

The Application of the Drugs of Bispecific Antibodies in Anti-Tumor Therapy

Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence

B-343 Development of CD40 and HER2 Bispecific Antibodies for Enhanced Efficacy against HER2-Positive Tumors

Principles and Current Clinical Landscape of NK Cell Engaging Bispecific Antibody Against Cancer

Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

A CLDN 18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy

Cmar_a_330637 6977..6987

A Transformable Supramolecular Bispecific Cell Engager for Augmenting Natural Killer and T Cell‐Based Cancer Immunotherapy

Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses

Corrigendum: Bispecific NK-cell Engager Targeting BCMA Elicits Stronger Antitumor Effects and Produces Less Proinflammatory Cytokines Than T-cell Engager